{"id":"https://openalex.org/W2009334783","doi":"https://doi.org/10.3816/cgc.2007.n.030","title":"Treatment of Advanced Renal Cell Carcinoma with the Combination Bevacizumab/Erlotinib/Imatinib: A Phase I/II Trial","display_name":"Treatment of Advanced Renal Cell Carcinoma with the Combination Bevacizumab/Erlotinib/Imatinib: A Phase I/II Trial","publication_year":2007,"publication_date":"2007-12-01","ids":{"openalex":"https://openalex.org/W2009334783","doi":"https://doi.org/10.3816/cgc.2007.n.030","mag":"2009334783","pmid":"https://pubmed.ncbi.nlm.nih.gov/18272024"},"language":"en","primary_location":{"id":"doi:10.3816/cgc.2007.n.030","doi":"https://doi.org/10.3816/cgc.2007.n.030","is_oa":false,"landing_page_url":"https://doi.org/10.3816/cgc.2007.n.030","pdf_url":null,"source":{"id":"https://openalex.org/S71328803","display_name":"Clinical Genitourinary Cancer","issn_l":"1558-7673","issn":["1558-7673","1938-0682"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Genitourinary Cancer","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5065917441","display_name":"John Daniel Hainsworth","orcid":"https://orcid.org/0000-0002-2848-6546","observed_orcids":["https://orcid.org/0000-0002-2848-6546"]},"institutions":[{"id":"https://openalex.org/I172427033","display_name":"Sarah Cannon Research Institute","ror":"https://ror.org/03cp5cj42","country_code":"GB","type":"education","lineage":["https://openalex.org/I172427033"]},{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["GB","US"],"is_corresponding":true,"raw_author_name":"John D. Hainsworth","raw_affiliation_strings":["Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN 37203, USA. jhainsworth@tnonc.com","Sarah Cannon Research Institute, and Tennessee Oncology, PLLC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN 37203, USA. jhainsworth@tnonc.com","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210135086"]},{"raw_affiliation_string":"Sarah Cannon Research Institute, and Tennessee Oncology, PLLC","institution_ids":["https://openalex.org/I172427033","https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018054038","display_name":"David Robert Spigel","orcid":"https://orcid.org/0000-0003-3215-9465","observed_orcids":["https://orcid.org/0000-0003-3215-9465"]},"institutions":[{"id":"https://openalex.org/I172427033","display_name":"Sarah Cannon Research Institute","ror":"https://ror.org/03cp5cj42","country_code":"GB","type":"education","lineage":["https://openalex.org/I172427033"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"David R. Spigel","raw_affiliation_strings":["Sarah Cannon Research Institute, and Tennessee Oncology, PLLC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute, and Tennessee Oncology, PLLC","institution_ids":["https://openalex.org/I172427033","https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075566772","display_name":"Jeffrey Alan Sosman","orcid":"https://orcid.org/0000-0002-0650-9698","observed_orcids":["https://orcid.org/0000-0002-0650-9698"]},"institutions":[{"id":"https://openalex.org/I200719446","display_name":"Vanderbilt University","ror":"https://ror.org/02vm5rt34","country_code":"US","type":"education","lineage":["https://openalex.org/I200719446"]},{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeffrey A. Sosman","raw_affiliation_strings":["Vanderbilt-Ingram Cancer Center, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vanderbilt-Ingram Cancer Center, Nashville, TN","institution_ids":["https://openalex.org/I200719446","https://openalex.org/I4390039299"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072308451","display_name":"Howard A. Burris","orcid":"https://orcid.org/0000-0002-1501-2931","observed_orcids":["https://orcid.org/0000-0002-1501-2931"]},"institutions":[{"id":"https://openalex.org/I172427033","display_name":"Sarah Cannon Research Institute","ror":"https://ror.org/03cp5cj42","country_code":"GB","type":"education","lineage":["https://openalex.org/I172427033"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"Howard A. Burris","raw_affiliation_strings":["Sarah Cannon Research Institute, and Tennessee Oncology, PLLC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute, and Tennessee Oncology, PLLC","institution_ids":["https://openalex.org/I172427033","https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044246734","display_name":"Cindy P. Farley","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I172427033","display_name":"Sarah Cannon Research Institute","ror":"https://ror.org/03cp5cj42","country_code":"GB","type":"education","lineage":["https://openalex.org/I172427033"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"Cindy Farley","raw_affiliation_strings":["Sarah Cannon Research Institute, and Tennessee Oncology, PLLC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute, and Tennessee Oncology, PLLC","institution_ids":["https://openalex.org/I172427033","https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075406468","display_name":"Heather Cucullu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I200719446","display_name":"Vanderbilt University","ror":"https://ror.org/02vm5rt34","country_code":"US","type":"education","lineage":["https://openalex.org/I200719446"]},{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Heather Cucullu","raw_affiliation_strings":["Vanderbilt-Ingram Cancer Center, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vanderbilt-Ingram Cancer Center, Nashville, TN","institution_ids":["https://openalex.org/I200719446","https://openalex.org/I4390039299"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041306590","display_name":"Kathleen J. Yost","orcid":"https://orcid.org/0000-0002-9641-5627","observed_orcids":["https://orcid.org/0000-0002-9641-5627"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kathleen Yost","raw_affiliation_strings":["Grand Rapids Clinical Oncology Program, MI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Grand Rapids Clinical Oncology Program, MI","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111656761","display_name":"Lowell L. Hart","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lowell L. Hart","raw_affiliation_strings":["Florida Cancer Specialists, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Florida Cancer Specialists, FL","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048320404","display_name":"Linda S. Sylvester","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Linda Sylvester","raw_affiliation_strings":["Integrated Community Oncology Network, Orange Park, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Integrated Community Oncology Network, Orange Park, FL","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053359739","display_name":"David Michael Waterhouse","orcid":"https://orcid.org/0000-0001-5589-9939","observed_orcids":["https://orcid.org/0000-0001-5589-9939"]},"institutions":[{"id":"https://openalex.org/I4210153992","display_name":"Oncology Hematology Care","ror":"https://ror.org/04gqr8882","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210153992"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David M. Waterhouse","raw_affiliation_strings":["Oncology Hematology Care, Cincinnati, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology Hematology Care, Cincinnati, OH","institution_ids":["https://openalex.org/I4210153992"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5073724595","display_name":"F. Anthony Greco","orcid":"https://orcid.org/0009-0009-4578-0630","observed_orcids":["https://orcid.org/0009-0009-4578-0630"]},"institutions":[{"id":"https://openalex.org/I172427033","display_name":"Sarah Cannon Research Institute","ror":"https://ror.org/03cp5cj42","country_code":"GB","type":"education","lineage":["https://openalex.org/I172427033"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"F. Anthony Greco","raw_affiliation_strings":["Sarah Cannon Research Institute, and Tennessee Oncology, PLLC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute, and Tennessee Oncology, PLLC","institution_ids":["https://openalex.org/I172427033","https://openalex.org/I4210135086"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":6,"corresponding_author_ids":["https://openalex.org/A5065917441"],"corresponding_institution_ids":["https://openalex.org/I172427033","https://openalex.org/I4210100810","https://openalex.org/I4210135086"],"apc_list":{"value":3530,"currency":"USD","value_usd":3530},"apc_paid":null,"fwci":4.9494,"has_fulltext":false,"cited_by_count":80,"citation_normalized_percentile":{"value":0.95004382,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":92,"max":98},"biblio":{"volume":"5","issue":"7","first_page":"427","last_page":"432"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11297","display_name":"Ferroptosis and cancer prognosis","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.9710000157356262},{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":1.0},{"id":"https://openalex.org/keywords/imatinib","display_name":"imatinib","score":1.0},{"id":"https://openalex.org/keywords/pdgf-receptor-inhibition","display_name":"PDGF receptor inhibition","score":0.8410000205039978},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.671999990940094},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.671999990940094},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8330000042915344},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.8270000219345093},{"id":"https://openalex.org/keywords/metastatic-renal-cell-carcinoma","display_name":"metastatic renal cell carcinoma","score":0.6899999976158142}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9370872974395752},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.8333495855331421},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.6987040042877197},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6223469972610474},{"id":"https://openalex.org/C2777472916","wikidata":"https://www.wikidata.org/wiki/Q1164529","display_name":"Renal cell carcinoma","level":2,"score":0.6173934936523438},{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.5589044690132141},{"id":"https://openalex.org/C2777583451","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib","level":3,"score":0.5339499711990356},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5265011191368103},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.44908589124679565},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.4125969707965851},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3753620684146881},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2673463225364685},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.24839457869529724},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.21370422840118408},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.08120882511138916}],"mesh":[{"descriptor_ui":"D000068258","descriptor_name":"Bevacizumab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000068877","descriptor_name":"Imatinib Mesylate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000069347","descriptor_name":"Erlotinib Hydrochloride","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001549","descriptor_name":"Benzamides","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002292","descriptor_name":"Carcinoma, Renal Cell","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D002292","descriptor_name":"Carcinoma, Renal Cell","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007680","descriptor_name":"Kidney Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D007680","descriptor_name":"Kidney Neoplasms","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D017479","descriptor_name":"Receptors, Platelet-Derived Growth Factor","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D040262","descriptor_name":"Receptors, Vascular Endothelial Growth Factor","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.3816/cgc.2007.n.030","doi":"https://doi.org/10.3816/cgc.2007.n.030","is_oa":false,"landing_page_url":"https://doi.org/10.3816/cgc.2007.n.030","pdf_url":null,"source":{"id":"https://openalex.org/S71328803","display_name":"Clinical Genitourinary Cancer","issn_l":"1558-7673","issn":["1558-7673","1938-0682"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Genitourinary Cancer","raw_type":"journal-article"},{"id":"pmid:18272024","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18272024","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical genitourinary cancer","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":20,"referenced_works":["https://openalex.org/W1590979348","https://openalex.org/W1978173977","https://openalex.org/W1979300931","https://openalex.org/W2046507292","https://openalex.org/W2105677187","https://openalex.org/W2105984177","https://openalex.org/W2125505202","https://openalex.org/W2127768463","https://openalex.org/W2128176473","https://openalex.org/W2139248078","https://openalex.org/W2143813821","https://openalex.org/W2149026055","https://openalex.org/W2149456801","https://openalex.org/W2155977433","https://openalex.org/W2206164324","https://openalex.org/W2241421448","https://openalex.org/W2305352133","https://openalex.org/W3010916979","https://openalex.org/W3041047318","https://openalex.org/W6635413076"],"related_works":["https://openalex.org/W3011650602","https://openalex.org/W2258666978","https://openalex.org/W2105984177","https://openalex.org/W2146711059","https://openalex.org/W2246106349","https://openalex.org/W3010916979","https://openalex.org/W1996347570","https://openalex.org/W2258529761","https://openalex.org/W2104540972","https://openalex.org/W2089561806"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":3},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":6}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}